Industry News

QLT to study potential treatment for Leber’s congenital amaurosis, RP

QLT Inc. announced that it will soon finalize a protocol for a clinical trial of QLT091001 for treating inherited retinal disease such as Leber’s congenital amaurosis and retinitis pigmentosa, according to a company press release.

The company said in the release that it has also begun recruiting subjects for a phase 2a proof-of-concept trial of this agent in adults with impaired dark adaptation.

In addition, QLT has launched a compassionate use program of QLT091001 in Leber’s congenital amaurosis and RP.

"We are excited with the progress QLT has made with the program this past year and look forward to a productive next few months as we prepare this important therapy for a pivotal trial,” QLT Chairman of the Board Jason M. Aryeh said in the release.

QLT Inc. announced that it will soon finalize a protocol for a clinical trial of QLT091001 for treating inherited retinal disease such as Leber’s congenital amaurosis and retinitis pigmentosa, according to a company press release.

The company said in the release that it has also begun recruiting subjects for a phase 2a proof-of-concept trial of this agent in adults with impaired dark adaptation.

In addition, QLT has launched a compassionate use program of QLT091001 in Leber’s congenital amaurosis and RP.

"We are excited with the progress QLT has made with the program this past year and look forward to a productive next few months as we prepare this important therapy for a pivotal trial,” QLT Chairman of the Board Jason M. Aryeh said in the release.